Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital and a Professor of Medicine at the Zucker School of Medicine, shared an article by Kathy D. Miller, et al. on LinkedIn:
“Excited to share my latest podcast episode with Dr. Kathy Miller, where we discuss the practical implications of HER2-Low and HER2-Ultralow breast cancer.
We explore how these evolving classifications impact treatment decisions and patient care.
Listen here.
A must-listen for oncologists, surgeons, researchers, and anyone interested in the future of precision oncology!”
New Classification of HER2–Ultra-Low Breast Cancer: What Do We Need to Know?
